Heart doctors are capturing images of the inside of heart arteries, helping them watch plaque respond to cholesterol drugs in ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A ...

It cannot be denied that statins have revolutionized how we treat and prevent coronary heart disease. But there are both external and intrinsic reasons why some patients do not respond adequately to ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert ...

PHILADELPHIA, PA—A novel, long-acting PCSK9 inhibitor that is injected just once every 3 months can reduce LDL-cholesterol levels by more than 50% compared with placebo in patients already taking ...

CINCINNATI (WKRC) -A new therapy could help a person lower his or her risk of having a heart attack. New research is explaining how. This new research showed that a single shot taken once a month can ...

NEW ORLEANS, LA—Use of enlicitide 20 mg, an oral PCSK9 inhibitor, significantly cut levels of LDL cholesterol and other atherogenic lipids in a large cohort of high-risk patients, results from the ...

A new experimental daily pill, Enlicitide, has shown a significant reduction in bad cholesterol by up to 60 per cent in ...

RAHWAY, N.J., November 08, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 ...